[go: up one dir, main page]

WO2006128035A3 - Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension - Google Patents

Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension Download PDF

Info

Publication number
WO2006128035A3
WO2006128035A3 PCT/US2006/020547 US2006020547W WO2006128035A3 WO 2006128035 A3 WO2006128035 A3 WO 2006128035A3 US 2006020547 W US2006020547 W US 2006020547W WO 2006128035 A3 WO2006128035 A3 WO 2006128035A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
enantiomer
furopyridine
disease
cicletanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020547
Other languages
French (fr)
Other versions
WO2006128035A2 (en
Inventor
Glenn Cornett
Jim Page
Karen Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navitas Pharma Inc
Original Assignee
Navitas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navitas Pharma Inc filed Critical Navitas Pharma Inc
Publication of WO2006128035A2 publication Critical patent/WO2006128035A2/en
Anticipated expiration legal-status Critical
Publication of WO2006128035A3 publication Critical patent/WO2006128035A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Embodiments of the invention include formulations and methods of use of furopyridine-based compositions alone and in combination with one or more various second therapeutic agents for the treatment of disease in human subjects. The furopyridine composition may include one or more furopyridine species, of which cicletanine as an example. The furopyridines may take various enantiomeric forms. Cicletanine, for example, may be present as (1) pure (+) enantiomer, (2) a non racemic mixture in which the (+) enantiomer is the major form and the (-) enantiomer is the minor form, (3) a racemic mixture in which the (+) and (-) enantiomers are equally present, (4) a non-racemic mixture in which the (-) enantiomer is the major form and the (+) enantiomer is the minor form, and (5) the pure (-) enantiomer. Second agents included in embodiments of the invention may be any drug that is useful in combination with a furopyridine composition in the treatment of disease. Such diseases may include, for example, heart disease, vascular disease, hypertension, diabetes, metabolic syndrome, polycystic ovarian syndrome, and autoimmune disorders. Some of these diseases commonly are associated with endothelial dysfunction and imbalances of imbalances of prostacyclin or of reactive oxygen species (ROS) or reactive nitrogen species (RNS). Second agents may include, for example, antihypertensive agents, such as beta blockers, aldosterone blockers, calcium antagonists, and metal supplements. In terms of mechanism of action, such second agents may advantageously include agents that increase prostacyclin activity, inhibit phosphodiesterase, inhibit protein kinases, or increase insulin sensitivity.
PCT/US2006/020547 2005-05-26 2006-05-26 Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension Ceased WO2006128035A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68468405P 2005-05-26 2005-05-26
US60/684,684 2005-05-26
US71302605P 2005-08-30 2005-08-30
US60/713,026 2005-08-30

Publications (2)

Publication Number Publication Date
WO2006128035A2 WO2006128035A2 (en) 2006-11-30
WO2006128035A3 true WO2006128035A3 (en) 2009-04-16

Family

ID=37452917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020547 Ceased WO2006128035A2 (en) 2005-05-26 2006-05-26 Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension

Country Status (1)

Country Link
WO (1) WO2006128035A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN102370653B (en) * 2010-08-18 2013-07-03 天津金耀集团有限公司 Application of eplerenone in preparing medicaments for treating pulmonary fibrosis
WO2015103445A1 (en) * 2013-12-31 2015-07-09 Rockey Don C Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions
CN104000790A (en) * 2014-04-28 2014-08-27 万特制药(海南)有限公司 Lacidipine dispersible tablet and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2004091632A1 (en) * 2003-04-15 2004-10-28 SynoSens Kutató és Fejlesztő Kft. A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor
WO2004098538A2 (en) * 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2004098538A2 (en) * 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
WO2004091632A1 (en) * 2003-04-15 2004-10-28 SynoSens Kutató és Fejlesztő Kft. A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SACK ET AL.: "Combination of Potassium, Calcium, and Magnesium Supplements in Hypertension", HYPERTENSION, vol. 26, 1995, pages 950 - 956 *

Also Published As

Publication number Publication date
WO2006128035A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
EA200602062A1 (en) AMIDOCONOMINATION AND THEIR APPLICATION AS PHARMACEUTICAL FACILITIES
NO20051102L (en) Sulfonylamino-acetic acid derivatives
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MX2009006001A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006039325A3 (en) Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2006020145A3 (en) Flt3 inhibitors for immune suppression
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
WO2004028516A3 (en) Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
UA86400C2 (en) Normal;heading 1;heading 2;USE OF LOW-DOSE ERYTHROPOIETIN FOR PATIENTS WITH DYSFUNCTION OF ENDOTHELIAL PRECURSOR CELLS, CARDIOVASCULAR RISK FACTOR AND END ORGAN DAMAGES
EP1541197B8 (en) Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
WO2006128035A3 (en) Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
WO2006020207A3 (en) Compounds for control of appetite
WO2005092878A3 (en) Schweinfurthin analogues
CA2357114A1 (en) Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
WO2005123651A8 (en) L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
WO2008085872A8 (en) Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
WO2004010924A3 (en) Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771360

Country of ref document: EP

Kind code of ref document: A2